Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations.
| FactSnippet No. 1,658,474 |
13 Facts About Boehringer Ingelheim
1.
2.
The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
| FactSnippet No. 1,658,475 |
3.
Boehringer Ingelheim agreed to make cash payments of up to $125 million based on performance milestones.
| FactSnippet No. 1,658,476 |
4.
Boehringer Ingelheim terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.
| FactSnippet No. 1,658,477 |
5.
Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe.
| FactSnippet No. 1,658,478 |
6.
Boehringer Ingelheim invested US$300,000,000 to upgrade the drug manufacturing plant, and limited production resumed in October 2012.
| FactSnippet No. 1,658,479 |
7.
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners.
| FactSnippet No. 1,658,480 |
8.
Boehringer Ingelheim is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
| FactSnippet No. 1,658,481 |
9.
On January 11th, 2021 Boehringer Ingelheim announced a collaborative agreement with Google Quantum AI, focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development, specifically including molecular dynamics simulations.
| FactSnippet No. 1,658,482 |
10.
Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing in a newly established Quantum Lab of Boehringer Ingelheim.
| FactSnippet No. 1,658,483 |
11.
Boehringer Ingelheim is a founding member of the Quantum Technology and Application Consortium.
| FactSnippet No. 1,658,484 |
12.
In October 2012 Boehringer Ingelheim settled a "qui tam" case with the US government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.
| FactSnippet No. 1,658,485 |
13.
In 2006, the Chairman of the Shareholders' Committee Dr Heribert Johann retired and Christian Boehringer Ingelheim took over the position as chairperson of the board of directors.
| FactSnippet No. 1,658,486 |